Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:BNXT)

0.6300 -0.0100 (-1.56%)
Streaming Delayed Price Updated: 3:40 PM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BNXT

< Previous 1 2 3 Next >
News headline image
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
Via ACCESS Newswire
News headline image
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
Via ACCESS Newswire
News headline image
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
Via ACCESS Newswire
News headline image
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
Via ACCESS Newswire
News headline image
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
Via ACCESS Newswire
News headline image
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
Via ACCESS Newswire
News headline image
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
VANCOUVER, BC / November 4, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF... 
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
Via ACCESS Newswire
News headline image
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
VANCOUVER, BC / October 30, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased... 
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
Via ACCESS Newswire
News headline image
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug
BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead... 
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
VANCOUVER, BC / October 21, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies,... 
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
Via ACCESS Newswire
News headline image
BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
Via ACCESS Newswire
News headline image
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
Via ACCESS Newswire
News headline image
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
Via ACCESS Newswire
News headline image
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
Via ACCESS Newswire
News headline image
BioNxt Advances Semaglutide Oral Dissolvable Film (ODF) Program with Successful Proof-of-Concept and Prototype Development
Via ACCESS Newswire
News headline image
BioNxt Solutions Completes Up-Listing to The OTCQB Market
Via ACCESS Newswire
News headline image
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
Via ACCESS Newswire
News headline image
BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
Via ACCESS Newswire
News headline image
BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation
Via ACCESS Newswire
News headline image
BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology
Via ACCESS Newswire
News headline image
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
Via ACCESS Newswire
News headline image
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
Via ACCESS Newswire
News headline image
BioNxt Solutions Provides Bi-weekly MCTO Status Report
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
Via ACCESS Newswire
News headline image
BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory
Via ACCESS Newswire
News headline image
BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
Via ACCESS Newswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.